GENMAB A/S (GMAB)
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Address
TOLDBODGADE 33
1253 COPENHAGEN K, G7 00000
Founded
1998
Number of Employees
2,204
Website
http://www.genmab.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)